H

Halozyme, Inc. Tech Stack

Biopharmaceutical enzyme technology platform enabling faster drug delivery

Biotechnology Research San Diego, California 201–500 employees Public Company

Halozyme licenses its proprietary ENHANZE® enzyme technology (rHuPH20) to major pharma partners, converting hours-long injected treatments into minutes. The company derives revenue through milestone payments and royalties as partners advance commercialized therapies. Hiring is heavily weighted toward sales (17 open roles) alongside legal and ops functions, reflecting a business model centered on partner management, reimbursement navigation, and commercial execution rather than internal R&D.

Tech Stack 11 technologies

Core StackSmartsheet NetSuite Workato OpenAI Anthropic Ironclad SharePoint Azure OpenAI AWS Bedrock Minitab Microsoft Project

What Halozyme, Inc. Is Building

◆Challenges

Ensuring access to antares products
Reimbursement policy barriers
Enhancing decision making speed
Complex licensing negotiations
Lack of real-time competitor monitoring
Complex strategic planning
Budget constraints
Cross-functional alignment
Expanding licensing portfolio
Ensuring on time delivery

▲Active Projects

Customizing sales presentations with segmentation data
Corporate m&a strategy
Data-driven sales presentations
Gtn accounting implementation
Driving new prescriptions for halozyme products
Licensing enhanze® technology
Licensing mdasetm technology
10-year strategic plan development
3pl partnership onboarding
Data and science-driven sales presentations

Hiring Activity

Accelerating35 roles · 15 in 30d

Department

Sales

17

Legal

3

Ops

3

Engineering

2

Executive

1

Finance

1

HR

1

Manufacturing

1

Seniority

Mid

10

Manager

6

Senior

6

Director

4

Junior

3

VP

3

Company intelligence

Find more companies like Halozyme, Inc. by tech stack, pain points and active projects

Get started free

About Halozyme, Inc.

Halozyme is a public biopharmaceutical company based in San Diego that develops and licenses the ENHANZE® platform — an enzyme-based delivery technology that accelerates subcutaneous drug administration. The company has licensed this technology to nine major pharmaceutical partners including Roche, Pfizer, Janssen, AbbVie, and Bristol-Myers Squibb. ENHANZE® has reached five commercialized products across more than 100 markets, impacting over 400,000 patient lives to date. Halozyme operates a partnership-driven model, generating revenue through collaboration milestones and royalties rather than direct drug sales. The company is scaling sales, legal, and operational functions to manage a growing portfolio of licensing agreements and navigate complex reimbursement and regulatory landscapes globally.

HeadquartersSan Diego, California

Company Size201–500 employees

Hiring MarketsUnited States

Frequently Asked Questions

What is Halozyme's main technology?

ENHANZE® — a proprietary enzyme (rHuPH20) that reduces injected biologic treatment times from hours to minutes, licensed to nine major pharmaceutical companies including Roche, Pfizer, and AbbVie.

What tech stack does Halozyme use?

Halozyme's primary tools include Smartsheet, NetSuite, SharePoint, Workato, Ironclad, and Azure OpenAI — a mix oriented toward contract management, ERP, workflow automation, and AI-assisted business operations.